Gene Therapy Clinical Trials
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Belumosudil 200 mg QD
- drug: Belumosudil 200 mg BID
- drug: Belumosudil 400 mg QD
Eligibility
Inclusion Criteria:
Subjects must have been treated with belumosudil for at least 1 of the following:
- Actively receiving belumosudil on Study KD025-208 or Study KD025-213
- Is in Long-term Follow-up (LTFU) on Study KD025-208 or Study KD025-213. Long-term
Follow-up will be defined as the period after ending treatment with belumosudil and
until a FFS event occurs.
- Adult enrolled in the Companion Study under KD025-213 Amendment 2 (01 June 2020) and
has received at least 6 months of treatment of belumosudil or is in LTFU
Exclusion Criteria:
- Female subject who is pregnant or breastfeeding
- Subject considered unlikely to adhere to treatment and/or follow protocol in the
opinion of the Investigator
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mandy Zeng
650-725-1647
Not Recruiting